148 related articles for article (PubMed ID: 2873245)
21. [Salazosulfapyridine in rheumatoid arthritis. A study of 49 patients].
Hilliquin P; Munoz A; Menkes CJ
Ann Med Interne (Paris); 1992; 143(3):149-54. PubMed ID: 1355956
[TBL] [Abstract][Full Text] [Related]
22. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Habal FM; Greenberg GR
Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
[TBL] [Abstract][Full Text] [Related]
23. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.
Capell HA; Maiden N; Madhok R; Hampson R; Thomson EA
J Rheumatol; 1998 Oct; 25(10):1880-6. PubMed ID: 9779839
[TBL] [Abstract][Full Text] [Related]
24. The use of the AIMS questionnaire in the evaluation of sulphasalazine treatment in rheumatoid arthritis.
Pelísková Z; Trnavský K; Vácha J
Z Rheumatol; 1987; 46(3):124-8. PubMed ID: 2442919
[TBL] [Abstract][Full Text] [Related]
25. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
Madhok R; Wijelath E; Smith J; Watson J; Sturrock RD; Capell HA
J Rheumatol; 1991 Feb; 18(2):199-202. PubMed ID: 1708829
[TBL] [Abstract][Full Text] [Related]
26. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?
Sheldon P; Webb C; Grindulis KA
Br J Rheumatol; 1988 Oct; 27(5):344-9. PubMed ID: 2902897
[TBL] [Abstract][Full Text] [Related]
27. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
Kovács A
Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
29. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
Kreisel W; Wolf LM; Grotz W; Grieshaber M
Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
[TBL] [Abstract][Full Text] [Related]
30. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
31. [The indications for the use of salazosulfapyridine in rheumatoid arthritis patients].
Taneichi K; Baba Y; Sakai I; Shibaki H
Ryumachi; 1994 Aug; 34(4):744-51. PubMed ID: 7974025
[TBL] [Abstract][Full Text] [Related]
32. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
Andreoli A; Spinella S; Levenstein S; Prantera C
Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
[TBL] [Abstract][Full Text] [Related]
33. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
Pullar T; Hunter JA; Capell HA
Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
[TBL] [Abstract][Full Text] [Related]
34. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Schölmerich J; Gerok W
Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of rheumatoid spondylarthritis with salazosulfapyridine].
Hilliquin P; Munoz A; Menkès CJ
Rev Rhum Mal Osteoartic; 1991; 58(7):535-41. PubMed ID: 1681585
[TBL] [Abstract][Full Text] [Related]
36. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
37. Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites.
Allgayer H; Sonnenbichler J; Kruis W; Paumgartner G
Arzneimittelforschung; 1985; 35(9):1457-9. PubMed ID: 2867770
[TBL] [Abstract][Full Text] [Related]
38. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
39. [Results of a clinical trial of sulfasalazine in rheumatoid arthritis].
Pelísková Z; Trnavský K; Gatterová J; Macek J
Vnitr Lek; 1989 Jan; 35(1):62-7. PubMed ID: 2564708
[TBL] [Abstract][Full Text] [Related]
40. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis.
Imai F; Suzuki T; Ishibashi T; Tanaka M; Akiyama Y; Dohi Y
J Rheumatol; 1994 Apr; 21(4):612-5. PubMed ID: 7913501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
